Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03748979
Recruitment Status : Completed
First Posted : November 21, 2018
Results First Posted : December 8, 2020
Last Update Posted : December 8, 2020
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925 when administered to healthy participants and narcolepsy participants.

Condition or disease Intervention/treatment Phase
Healthy Participants Narcolepsy Drug: TAK-925 Drug: Placebo Phase 1

Detailed Description:

The drug being tested in this study is called TAK-925. TAK-925 is being tested in healthy participants and participants with narcolepsy. This study will look at the safety, tolerability, pharmacokinetics, and efficacy of TAK-925.

This study will consist of three parts. Part A will be a randomized, double-blind, placebo-controlled, multiple rising dose (MRD) study in healthy participants. Part B is a randomized, double-blind, placebo-controlled MRD study in participants with narcolepsy. Part C is a randomized, double-blind, placebo-controlled, parallel group, multiple repeat dose study in participants with narcolepsy. Part A' is a single dose study in healthy participants.

The study will enroll approximately 96 participants planned as total. All participants except Part A' will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need):

Part A:

  • TAK-925 (Dose Levels A1-A6)
  • Placebo

Part B:

  • TAK-925 (Dose Levels B1-B4)
  • Placebo

Part C:

  • TAK-925 (Dose Levels C1-C2)
  • Placebo

Part A':

• TAK-925 (Dose Levels A'1-A'2)

All participants will be asked to take TAK-925 or Placebo at the same time each day from Day 1 to Day 7 in Parts A, B and C, and take TAK-925 on Day 1 in Part A'.

This multi-center trial will be conducted in Japan. The overall study period is approximately 15 days in Parts A, B and C, and approximately 7 days for Part A'. Participants will be partly admitted to a hospital during the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy
Actual Study Start Date : November 21, 2018
Actual Primary Completion Date : October 24, 2019
Actual Study Completion Date : October 24, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort A1; TAK-925 (Dose Level A1)
TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
Drug: TAK-925
TAK-925

Experimental: Cohort A2; TAK-925 (Dose Level A2)
TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort A3; TAK-925 (Dose Level A3)
TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort A4; TAK-925 (Dose Level A4)
TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort A5; TAK-925 (Dose Level A5)
TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort A6; TAK-925 (Dose Level A6)
TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Placebo Comparator: Part A (Cohorts A1-A6); TAK-925 Placebo
TAK-925 Placebo, once daily for up to 7 days in healthy participants.
Drug: Placebo
TAK-925 Placebo

Experimental: Cohort B1; TAK-925 (Dose Level B1)
TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
Drug: TAK-925
TAK-925

Experimental: Cohort B2; TAK-925 (Dose Level B2)
TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort B3; TAK-925 (Dose Level B3)
TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort B4; TAK-925 (Dose Level B4)
TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Placebo Comparator: Part B (Cohorts B1-B4); TAK-925 Placebo
TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
Drug: Placebo
TAK-925 Placebo

Experimental: Cohort C1; TAK-925 (Dose Level C1)
TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Experimental: Cohort C2; TAK-925 (Dose Level C2)
TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925

Placebo Comparator: Part C (Cohorts C1-C2); TAK-925 Placebo
TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
Drug: Placebo
TAK-925 Placebo

Experimental: Cohort A'1; TAK-925 (Dose Level A'1)
TAK-925, Dose Level A'1, single dose in healthy participants.
Drug: TAK-925
TAK-925

Experimental: Cohort A'2; TAK-925 (Dose Level A'2)
TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
Drug: TAK-925
TAK-925




Primary Outcome Measures :
  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From the first dose of study drug up to 7 days after the last dose of study drug (up to Day 15) ]
    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with an onset that occurs after receiving study drug.


Secondary Outcome Measures :
  1. Parts A, B and C; Ceoi: Observed Plasma Concentration at the End of Infusion for TAK-925 [ Time Frame: Part A,Days 1,7:pre-infusion(inf),0.5,1, 1.5, 2, 4, 6, 8, 9 hours(h)post start of inf;0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 6, 10, 15 h post end of inf;Part B,C:Days 1,7:Pre-inf, 1, 2, 4, 6, 9 h post start of inf; 0.17, 0.5, 2, 6, 10, 15 h post end of inf ]
    This assessment was pre-specified to be conducted for participants in "Part A', Cohort A'1: TAK-925 112 mg" as exploratory measures.

  2. Parts A, B and C; AUCtau: Area Under the Plasma Concentration-Time Curve During a Dosing Interval for TAK-925 [ Time Frame: Part A,Days 1,7:pre-infusion(inf),0.5,1, 1.5, 2, 4, 6, 8, 9 hours(h)post start of inf;0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 6, 10, 15 h post end of inf;Part B,C:Days 1,7:Pre-inf, 1, 2, 4, 6, 9 h post start of inf; 0.17, 0.5, 2, 6, 10, 15 h post end of inf ]
    This assessment was pre-specified to be conducted for participants in "Part A', Cohort A'1: TAK-925 112 mg" as exploratory measures.

  3. Parts A, B and C; Rac (AUC): Accumulation Ratio Based on AUCtau for TAK-925 [ Time Frame: Part A,Days 1,7:pre-infusion(inf),0.5,1, 1.5, 2, 4, 6, 8, 9 hours(h)post start of inf;0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 6, 10, 15 h post end of inf;Part B,C:Days 1,7:Pre-inf, 1, 2, 4, 6, 9 h post start of inf; 0.17, 0.5, 2, 6, 10, 15 h post end of inf ]
    Accumulation Ratio of AUC was calculated as AUCtau on Day 7 divided by AUCtau on Day 1. This assessment was pre-specified to be conducted for participants in "Part A', Cohort A'1: TAK-925 112 mg" as exploratory measures.

  4. Parts B and C: Change From Baseline in Sleep Latency in the Maintenance of Wakefulness Test (MWT) at Days 1 and 7 [ Time Frame: Baseline, Day 1 and Day 7 ]
    The MWT is a validated objective measure that is used to measure excessive daytime sleepiness in clinical studies. It has been used as a secondary outcome measure for excessive daytime sleepiness. The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Wakefulness in this study was measured indirectly by time to fall asleep using MWT. In this study, four 40-minute (1 session) MWT assessments per day was administered on Baseline, Day 1 and Day 7. MWT sleep latency ranges from 0 to 40 minutes, with longer sleep latency indicating greater ability to stay awake.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy adult participants and Healthy elderly participants:

• Participant weighs at least 50 kg (Healthy adults participants) / 40 kilogram (kg) (Healthy elderly participants) and has a body mass index (BMI) from 18.5 to 30 kilogram per square meter (kg/m^2), inclusive at Screening.

Narcolepsy participants:

  • Participants weighs at least 40 kg inclusive at Screening (>=50 kg is required for Cohort B4).
  • A diagnosis of narcolepsy, as defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3).
  • At Day -1, Epworth sleepiness scale (ESS) score >=10

Exclusion Criteria:

All Participants:

  • Participants consume excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
  • Participants have a moderate to severe substance use disorder.
  • Participants have a risk of suicide according to endorsement of item 4 or 5 with Screening/Baseline visit C-SSRS (Columbia Suicide Severity Rating Scale) or has made a suicide attempt in the previous 6 months.
  • Participants have a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia.
  • Participants experienced sleep wake cycle disturbance with external factors such as irregular work hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748979


Locations
Layout table for location information
Japan
Sumida Hospital
Sumida-ku, Tokyo, Japan
Hakata Clinic
Fukuoka, Japan
PS Clinic
Fukuoka, Japan
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Takeda
  Study Documents (Full-Text)

Documents provided by Takeda:
Statistical Analysis Plan  [PDF] October 28, 2019
Study Protocol  [PDF] June 12, 2019

Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT03748979    
Other Study ID Numbers: TAK-925-1003
U1111-1221-3144 ( Other Identifier: WHO )
JapicCTI-184207 ( Registry Identifier: JapicCTI )
First Posted: November 21, 2018    Key Record Dates
Results First Posted: December 8, 2020
Last Update Posted: December 8, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://vivli.org/ourmember/takeda/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Narcolepsy
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders